<DOC>
	<DOCNO>NCT02627144</DOCNO>
	<brief_summary>This non-interventional , multicenter study evaluate efficacy safety intravenous bevacizumab ( Avastin ) combination interferon alpha-2a immunotherapy first-line treatment participant advance and/or metastatic renal cell cancer ( mRCC ) daily routine .</brief_summary>
	<brief_title>Bevacizumab Metastatic Renal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically confirm advanced and/or metastatic renal cell cancer No contraindication Avastin accord summary product characteristic ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic renal cell carcinoma</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>